Zürcher Nachrichten - Study shows how fast kilos return after ending weight-loss drugs

EUR -
AED 4.330578
AFN 75.468553
ALL 95.370831
AMD 434.26718
ANG 2.110613
AOA 1082.496254
ARS 1649.279971
AUD 1.625347
AWG 2.125489
AZN 2.009303
BAM 1.955202
BBD 2.368676
BDT 144.305864
BGN 1.967008
BHD 0.444064
BIF 3500.4294
BMD 1.179189
BND 1.491244
BOB 8.126515
BRL 5.795828
BSD 1.17604
BTN 111.057033
BWP 15.789171
BYN 3.323484
BYR 23112.111202
BZD 2.365277
CAD 1.612129
CDF 2670.864298
CHF 0.916177
CLF 0.026704
CLP 1050.508704
CNY 8.019372
CNH 8.014083
COP 4394.855841
CRC 540.634648
CUC 1.179189
CUP 31.248518
CVE 110.231286
CZK 24.334582
DJF 209.425947
DKK 7.476537
DOP 69.938609
DZD 156.038276
EGP 62.195977
ERN 17.68784
ETB 183.631137
FJD 2.574218
FKP 0.86512
GBP 0.864889
GEL 3.154379
GGP 0.86512
GHS 13.247948
GIP 0.86512
GMD 86.674958
GNF 10318.844
GTQ 8.979254
GYD 246.064742
HKD 9.234999
HNL 31.264438
HRK 7.538916
HTG 153.972908
HUF 353.981307
IDR 20491.303919
ILS 3.421187
IMP 0.86512
INR 111.345548
IQD 1540.628801
IRR 1546506.829043
ISK 143.873347
JEP 0.86512
JMD 185.35331
JOD 0.836092
JPY 184.753623
KES 151.883547
KGS 103.085327
KHR 4718.556838
KMF 492.90156
KPW 1061.270109
KRW 1723.880942
KWD 0.36279
KYD 0.9801
KZT 543.543758
LAK 25791.111834
LBP 105315.489444
LKR 378.634195
LRD 215.803997
LSL 19.293799
LTL 3.48184
LVL 0.71328
LYD 7.436725
MAD 10.75591
MDL 20.110849
MGA 4912.497521
MKD 61.621153
MMK 2475.640798
MNT 4221.622084
MOP 9.4824
MRU 47.006623
MUR 55.210091
MVR 18.163925
MWK 2038.876413
MXN 20.255648
MYR 4.623647
MZN 75.362436
NAD 19.293799
NGN 1609.593864
NIO 43.276764
NOK 10.859513
NPR 177.691653
NZD 1.976185
OMR 0.453611
PAB 1.17604
PEN 4.066156
PGK 5.193412
PHP 71.358689
PKR 327.765953
PLN 4.239717
PYG 7183.802847
QAR 4.298685
RON 5.21945
RSD 117.334114
RUB 87.543025
RWF 1724.072695
SAR 4.44258
SBD 9.456429
SCR 17.539736
SDG 708.107537
SEK 10.86706
SGD 1.494509
SHP 0.880384
SLE 29.067455
SLL 24727.006491
SOS 672.094441
SRD 44.100547
STD 24406.83871
STN 24.492509
SVC 10.290853
SYP 130.395965
SZL 19.281103
THB 37.973479
TJS 10.972544
TMT 4.127163
TND 3.415955
TOP 2.839205
TRY 53.473293
TTD 7.970562
TWD 36.927538
TZS 3063.662984
UAH 51.6595
UGX 4406.652233
USD 1.179189
UYU 46.905654
UZS 14265.63688
VES 588.693738
VND 31022.113342
VUV 138.276182
WST 3.19218
XAF 655.756438
XAG 0.014675
XAU 0.00025
XCD 3.186819
XCG 2.119552
XDR 0.815551
XOF 655.756438
XPF 119.331742
YER 281.384102
ZAR 19.315959
ZMK 10614.123377
ZMW 22.390152
ZWL 379.698489
  • CMSD

    0.1140

    23.534

    +0.48%

  • GSK

    -0.0900

    50.41

    -0.18%

  • RIO

    2.2700

    105.38

    +2.15%

  • RBGPF

    0.7000

    63.61

    +1.1%

  • BTI

    0.2000

    58.28

    +0.34%

  • BCE

    -0.4300

    24.14

    -1.78%

  • RYCEF

    -0.4100

    16.37

    -2.5%

  • CMSC

    0.1400

    23.11

    +0.61%

  • VOD

    0.5100

    16.2

    +3.15%

  • NGG

    0.9800

    86.89

    +1.13%

  • JRI

    0.0000

    13.15

    0%

  • BCC

    -2.0900

    70.67

    -2.96%

  • RELX

    0.0759

    33.58

    +0.23%

  • BP

    -0.4700

    43.34

    -1.08%

  • AZN

    0.3300

    182.85

    +0.18%

Study shows how fast kilos return after ending weight-loss drugs
Study shows how fast kilos return after ending weight-loss drugs / Photo: Armend NIMANI - AFP/File

Study shows how fast kilos return after ending weight-loss drugs

When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.

Text size:

But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.

A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.

They have been found to help people lose between 15-20 percent of their body weight.

"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.

However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.

This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.

So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.

Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.

While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.

However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.

The researchers projected that the participants would return to their original weight in 18 months.

Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.

People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.

This meant that people taking the drugs regained their weight four times faster.

- 'Starting point, not a cure' -

"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.

But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.

This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.

Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."

"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.

If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.

"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.

"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.

A.Ferraro--NZN